This study was published in Transplantation 2013 Nov 26
Study title and authors:
HMG CoA Reductase Inhibitor Treatment Induces Dysglycemia in Renal Allograft Recipients.
Choe EY, Wang HJ, Kwon O, Cho Y, Huh KH, Kim MS, Kim YS, Ahn CW, Cha BS, Lee HC, Kang ES.
Division of Endocrinology and Metabolism, Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea.
This study can be accessed at: http://www.ncbi.nlm.nih.gov/pubmed/24285338
The aim of this study was to evaluate the influence of statins on the development of dysglycemia in kidney transplant patients. (Dysglycemia is defined as diabetes and impaired fasting glucose). The study included 394 patients without previously known diabetes or impaired fasting glucose who had undertaken kidney transplantation. Patients were grouped into the two groups according if they used statins (245 statin users and 149 nonusers).
The study found:
(a) Statin users had a 208% increased risk of dysglycemia compared to non users.
(b) The time to development of dysglycemia after transplantation was shorter in the statin group (38.8 months) than in the control group (47.2 months).
Choe concluded: "Statin treatment is associated with an elevation in fasting plasma glucose and in the development of dysglycemia in renal allograft recipients (kidney transplant patients)".